Figure 1.

PFS and OS curves for patients treated with gefitinib. (A) PFS by EGFR mutation status measured in tumor tissue by Scorpion-ARMS. (B) PFS by EGFR mutation status measured in peripheral blood DNA by DHPLC. (C) PFS by EGFR mutation status measured in peripheral blood DNA by Scorpion-ARMS. (D) PFS by EGFR mutation status measured in peripheral blood DNA by ME-Liquidchip. (E) OS by EGFR mutation status measured in tumor tissue by Scorpion-ARMS. (F) OS by EGFR mutation status measured in peripheral blood DNA by DHPLC. (G) OS by EGFR mutation status measured in peripheral blood DNA by Scorpion-ARMS. (H) OS by EGFR mutation status measured in peripheral blood DNA by ME-Liquidchip.

Abbreviations: PFS, progression-free survival; OS, overall survival; EGFR, epidermal growth factor receptor; Scorpion-ARMS, Scorpion Amplification Refractory Mutation System; DHPLC, denaturing high-performance liquid chromatography; ME-Liquidchip, mutant-enriched liquidchip.